Abstract
Gene therapy is suggested to be one of the most specific and efficient modulations for gene deficient diseases and extended to other diseases like cancer and inflammation, even though there are still challenges to be faced, such as specific and selective delivery, minimal to no toxicity, efficient metabolism, simplicity, and measurable efficiency. It is important to identify and validate drug-able disease-specific targets for molecular and cellular therapies, while it is equally important to have disease biomarkers to trace and define the biological effects of molecular and cellular therapies. The importance and significance of allostery in molecular and cellular therapies and "allosteric disease", "allosteric effect", and "allosteric drug" should be more carefully examined and validated. Cell therapy has been attracting an increasing amount of consideration in the development of new treatments for diseases. Molecular and Cellular Therapies (MCT) is a new, open-access journal, devoted to molecular mechanisms, preclinical and clinical research and development of gene-, peptide-, protein-, and cell-based therapies.
Keywords
Cellular therapy
Disease
Journal
Molecular therapy
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Wang Xiangdong
Shanghai Institute of Respiratory Diseases; Department of Respiratory Medicine, Fudan University Zhongshan Hospital, Shanghai, Sweden ; Institute of Clinical Science, Lund University, Lund, Sweden.
Peer Dan
Department of Cell Research & Immunology, Laboratory of NanoMedicine, and the center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, Israel.
Petersen Bryon
Department of Pediatrics, University of Florida, Children Health Research Institute, Gainesville, FL USA.
References (16)
16 references, click to expand
-
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Science. 2013 May 3;340(6132):622-6
PMID: 23558173
-
Nanocarriers as an emerging platform for cancer therapy.
Nat Nanotechnol. 2007 Dec;2(12):751-60
PMID: 18654426
-
Translating dosage compensation to trisomy 21.
Nature. 2013 Aug 15;500(7462):296-300
PMID: 23863942
-
Systems of Mating. V. General Considerations.
Genetics. 1921 Mar;6(2):167-78
PMID: 17245962
-
Single-stranded siRNAs activate RNAi in animals.
Cell. 2012 Aug 31;150(5):883-94
PMID: 22939618
-
Allostery in disease and in drug discovery.
Cell. 2013 Apr 11;153(2):293-305
PMID: 23582321
-
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target.
Science. 2008 Feb 1;319(5863):627-30
PMID: 18239128
-
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.
Cell. 2012 Aug 31;150(5):895-908
PMID: 22939619
-
CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
Blood. 2013 Aug 15;122(7):1233-42
PMID: 23838350
-
RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice.
Mol Ther. 2010 Feb;18(2):370-6
PMID: 19997090
-
A daunting task: manipulating leukocyte function with RNAi.
Immunol Rev. 2013 May;253(1):185-97
PMID: 23550647
-
Role of the extracellular matrix in regulating stem cell fate.
Nat Rev Mol Cell Biol. 2013 Aug;14(8):467-73
PMID: 23839578
-
Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair.
Nat Rev Mol Cell Biol. 2013 Aug;14(8):529-41
PMID: 23839576
-
The Distribution of Gene Frequencies Under Irreversible Mutation.
Proc Natl Acad Sci U S A. 1938 Jul;24(7):253-9
PMID: 16577841
-
Opportunities and challenges of disease biomarkers: a new section in the Journal of Translational Medicine.
J Transl Med. 2012 Nov 07;10:220
PMID: 23134706
-
Clinical bioinformatics: a new emerging science.
J Clin Bioinforma. 2011 Jan 20;1(1):1
PMID: 21884620